TrialDiabetes, obesity & metabolism2025

Liraglutide improves peripheral perfusion and markers of angiogenesis and inflammation in people with type 2 diabetes and peripheral artery disease: An 18-month follow-up of a randomized clinical trial.

Paola Caruso et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.